Baxter Q3 2024: continuing ops sales +4% to $2.7B; adj. EPS $0.80 beats guidance

BAXTER INTERNATIONAL INC

2024-Q3 EPS reported -$0.27 revenue$7,883,000,000

Total sales (incl. discontinued ops) $3.85B; continuing ops sales $2.70B +4% YoY.
GAAP diluted EPS from continuing ops $0.12; adjusted continuing ops EPS $0.49.
Total Baxter GAAP diluted EPS $0.27; adjusted total diluted EPS $0.80, exceeding prior guidance.
North Cove facility restarted highest-throughput IV solutions line after Hurricane Helene.
Pending sale of Kidney Care business is a key milestone; hurricane expected to impact near-term financials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.